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ABSTRACT
Introduction: A recent study demonstrated
that large glucose fluctuations were associated
with an increased incidence of cardiovascular
disease (CVD) in patients with type 2 diabetes
mellitus (T2DM) and acute myocardial infarc-
tion. However, it is unknown whether glucose
fluctuations are related to the incidence of CVD
or the progression of atherosclerosis in patients
with T2DM with no apparent history of CVD. In
this protocol, we will be investigating the
relationships of glucose fluctuations evaluated
by continuous glucose monitoring (CGM) to
the incidence of composite cardiovascular
events and the progression of atherosclerosis in
patients with T2DM who had no apparent his-
tory of CVD.
Methods: This is a prospective, multicenter,
5-year follow-up observational study. Between
April 2018 and October 2019, 1000 participants
are expected to be recruited at 34 medical
institutions. CGM using FreeStyle Libre Pro is
useful for evaluating glucose fluctuations by
continuously monitoring glucose levels in
interstitial fluid for up to 14 days. The primary
study outcome is the relationship between
fluctuations in glucose levels evaluated by CGM
and the incidence of composite cardiovascular
events. Secondary outcomes include the rela-
tionships of fluctuations in glucose levels eval-
uated by CGM to changes in carotid intima
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media thickness evaluated by echography or
grayscale median (an index of tissue character-
istics of the carotid wall), brachial–ankle pulse
wave velocity, development or progression of
diabetic retinopathy or nephropathy, quality-
of-life-related diabetes therapy, quality of sleep,
development of dementia, and autonomic
nerve function.
Planned Outcome: This protocol is designed to
investigate the relationship between glucose
fluctuations and the incidence of composite
cardiovascular events. We completed the regis-
tration of 1000 participants in March 2019.
Thus, results will be available in 2024. We
expect that evaluating glucose fluctuations will
aid the identification of patients with a high
probability of developing CVD.
Trial Registration: ClinicalTrials.gov identifier,
UMIN000032325.
Keywords: Cardiovascular disease; Continuous
glucose monitoring; Glucose fluctuation;
Progression of atherosclerosis; Type 2 diabetes
mellitus
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is an inde-
pendent risk factor for cardiovascular disease
(CVD), which is one of the main causes of death
in patients with type 2 diabetes melli-
tus (T2DM). Taking preventive measures against
CVD in patients with T2DM is an urgent task
that is necessary to maintain their quality of
life, extend healthy lifespans, and reduce the
costs incurred by the social healthcare system.
The UK Prospective Diabetes Study showed
that every 1% decrease in the level of HbA1c
was associated with a decrease in the incidence
of CVD [1]. That study highlighted the impor-
tance of glycemic control in terms of preventing
CVD in patients with T2DM. However, other
large clinical trials have failed to show that
intensive glycemic control has beneficial effects
on the prevalence of CVD in T2DM [2–4].
On the other hand, recent clinical studies
have suggested that, in patients with T2DM,
glucose fluctuations are more significantly
associated with atherosclerotic-related diseases
than the degree of hyperglycemic exposure (as
indicated by HbA1c levels) is [5, 6]. In addition,
a recent study demonstrated that large glucose
fluctuations were associated with higher subse-
quent incidence rates of myocardial infarction,
acute heart failure, and cardiac death in patients
with acute myocardial infarction [7] and
patients with both T2DM and acute myocardial
infarction [8]. Thus, evaluating glucose fluctu-
ations may aid the identification of patients
with a high probability of developing CVD.
Such patients are often not identified by mea-
surements of HbA1c alone. However, it is
unknown whether glucose fluctuations are
related to the incidence of CVD or to the pro-
gression of atherosclerosis, especially in patients
with T2DM and no apparent history of CVD. It
is important to investigate these relationships
in order to identify new treatment targets for
preventing CVD.
The FreeStyle Libre Pro (FLP) continuous
glucose monitoring (CGM) (FLP-CGM) system
is useful for evaluating glucose fluctuations by
continuously monitoring glucose levels in
interstitial fluid every 15 min for up to 14 days.
FLP-CGM is also considerably cheaper than
conventional CGM and does not require cali-
bration by self-monitoring blood glucose levels
[9]. These positive aspects of FLP-CGM may
reduce patient burden. In addition, the accu-
racy and utility of the FreeStyle Libre system in
patients with T2DM have already been demon-
strated [10].
In this protocol, we will mainly be investi-
gating the relationships of glucose fluctuations
evaluated by FLP-CGM to the incidence of
composite cardiovascular events and the pro-
gression of atherosclerosis, including carotid
intima media thickness (IMT) progression and
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brachial-ankle pulse wave velocity (baPWV), in
1000 patients with T2DM who have no appar-
ent history of CVD. In addition, we will be
investigating the relationships of glucose fluc-
tuations evaluated by FLP-CGM to the devel-
opment or progression of diabetic retinopathy
or nephropathy, quality-of-life-related diabetes
therapy, quality of sleep, dementia develop-
ment, and autonomic nerve function.
METHODS
Study Design
This is a prospective, multicenter, observational
study. This study has been registered in the
University Hospital Medical Information Net-
work Clinical Trials Registry (UMIN-CTR),
which is a nonprofit organization in Japan that
meets the requirements of the International
Committee of Medical Journal Editors (ICMJE)
(UMIN000032325).
Study Population
The study population consists of Japanese
patients with T2DM who regularly attend the
outpatient diabetes clinics of 34 institutions
across Japan that were asked to participate in
this study (see Table S1 of the Electronic sup-
plementary material, ESM, for a list of those
institutions and the investigators involved in
the study).
The inclusion criteria are as follows:
(1) C 30 years of age and B 80 years of age (re-
gardless of gender); (2) receiving treatment for
T2DM at one of the above outpatient clinics; (3)
a signed consent form for participation in the
study is provided; (4) no changes (including
new prescriptions) in antidiabetic medications
for 6 months before written informed consent is
obtained (insulin dosage changes are allowed);
and no changes in antidiabetic medication are
anticipated from the time of enrollment until
FLP sensors are applied to the back of the upper
arm (insulin dosage changes are allowed). In
order to check whether the inclusion criteria are
met, the investigators are advised to confirm the
patient’s information, including their medica-
tion history, by checking medical records and/
or questioning the patient. The following
exclusion criteria are also applied: (1) type 1 or
secondary diabetes; (2) presence of severe
infectious disease pre- or postoperatively, or
severe trauma; (3) history of myocardial infarc-
tion, angina pectoris, cerebral stroke, cerebral
infarction, or arteriosclerosis obliterans; (4)
current treatment with artificial dialysis; (5)
moderate liver dysfunction (aspartate amino-
transferase C 100 IU/l); (6) moderate or severe
heart failure (New York Heart Association stage
III or worse); (7) pregnancy, lactation, possible
pregnancy, or the patient intends to become
pregnant during the study period; (8) present or
past history of a malignant tumor (however,
patients not currently receiving medication for
a malignant tumor, with no disease recurrence
to date, and with no risk of recurrence during
this study are allowed to participate); (9) use of a
sensor-augmented insulin pump; (10) a T2DM
diagnosis within the past year; and (11) judged
as ineligible by the clinical investigators.
The subjects are screened consecutively, and
patients who meet the above eligibility criteria
are asked to participate in the present study. All
patients who agree to participate are entered
into the study. The protocol was approved by
the institutional review board of each partici-
pating institution in compliance with the Dec-
laration of Helsinki and current legal
regulations in Japan. The chief ethics commit-
tee among those of all the participating insti-
tutions was the hospital ethics committee of
Juntendo University Hospital, as shown in
Table S2 of the ESM. Written informed consent
must be obtained from all participants after
they have received a full explanation of the
study.
Observation Variables and Schedule
The observation parameters and schedule are
shown in Table 1 and Fig. 1. The study period is
260 weeks after patient registration (registration
period: April 2018 to October 2019; full study
duration: April 2018 to December 2024).
Patients will visit each study institution for
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routine visits during the study period. Each
patient’s demographic data, clinical character-
istics, past medical history, lifestyle habits, and
treatment history will be collected at baseline
using a standardized case record form after
informed consent is provided. This is an obser-
vational study, and all treatment decisions will
be made by the treating investigators according
to usual care protocols. All patients will be fol-
lowed until the end of the scheduled study
period regardless of any change in treatment for
diabetes or other conditions. The general
health, blood pressure, and diet and exercise
status of each patient will be checked at each
visit. The clinical outcome of each patient will
be ascertained. Clinical and biochemical data
will be collected at baseline with a ± 10-week
buffer period, and every 52 weeks with a ± 12-
week buffer period. Blood samples will be
obtained after overnight fasting at baseline and
every 52 weeks thereafter. White blood cell
count, red blood cell count, hemoglobin,
hematocrit, platelet count, aminotransferase,
alanine aminotransferase, c-glutamyl transpep-
tidase, creatinine, uric acid lipids, total choles-
terol, low-density lipoprotein cholesterol
(estimated by the Friedewald equation), high-
density lipoprotein cholesterol, triglyceride,
HbA1c (National Glycohemoglobin Standard-
ization Program), and glucose will be measured
with standard techniques. The estimated
glomerular filtration rate (eGFR) will be calcu-
lated using the formula: eGFR (ml/min per
1.73 m2) = 194 9 age-0.287 9 serum
Table 1 Items and schedule
Registration Treatment period (weeks)
Baseline 52 weeks 104 weeks 156 weeks 208 weeks 260 weeks
Informed consent s
Patient characteristics s
Continuous glucose monitoring s 4
Outcomes s s s s s s
Body weight s s s s s s
Blood pressure s s s s s s
Blood chemistry* s s s s s s
Urinary albumin excretion s s s s s s
Carotid arterial echography 4 4 4
baPWV and ABI 4 4 4
Electrocardiogram 4 4 4
Diabetes Therapy-Related
Quality of Life questionnaire
4 4 4
Pittsburgh Sleep Quality Index
questionnaire
4 4 4
Cardiovascular events
baPWV brachial-ankle pulse wave velocity, ABI ankle brachial blood pressure index, 4 optional examination
*Including red blood cells, white blood cells, hemoglobin, hematocrit, blood platelet count, aspartate aminotransferase,
alanine aminotransferase, c-glutamyl transpeptidase, creatinine, estimated glomerular filtration rate, uric acid, total
cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, fasting plasma glucose,
HbA1c
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creatinine-0.1094 (9 0.739 for females). Urinary
albumin excretion will be measured by a latex
agglutination assay using a spot urine sample at
baseline and every 52 weeks thereafter. The
incidence of CVD will be recorded during the
260-week follow-up period.
Continuous Glucose Monitoring Using
the Freestyle Libre Pro
The FLP sensors are placed on the back of the
upper arm of each participant by well-trained
health care providers, and left in place for
14 days. There are no restrictions on partici-
pants’ daily lives. The FLP system continuously
measures the glucose concentration in the
interstitial fluid immediately below the skin.
After the sensor is removed, it is mailed to the
research support center (Soiken Inc., Tokyo,
Japan). Data are downloaded from the FLP sys-
tem and an ambulatory glucose profile is pro-
duced. The investigators and participants are
provided with these data at the outpatient clinic
appointment scheduled within 3 months after
FLP-CGM. Based on the results of FLP-CGM,
either the current therapy dose is increased or
additional diabetes treatment is prescribed.
Glucose fluctuations are assessed by measuring
the mean amplitude of glycemic excursion
(MAGE) [11], the standard deviation (SD), the
glucose coefficient of variation (CV), the aver-
age daily risk range (ADRR) [12], and the
M value, among other parameters.
MAGE is calculated as the arithmetic mean
of the differences between consecutive peaks
and nadirs, provided that the differences are
greater than 1 SD of the mean glucose value. CV
(%) is calculated by dividing the SD by the mean
of the corresponding glucose readings. ADRR is
computed by transforming blood glucose data
to a symmetric scale, converting blood glucose
measures to risk values, and eliminating values
within the normal range, then averaging the
daily out-of-range levels. The M value is a mea-
sure based on a weighted average of the mean
and the glucose range. It is a logarithmic
transformation of the deviation of blood glu-
cose from an arbitrarily assigned ideal glucose
level. Hypoglycemia is defined as the
Fig. 1 Flow chart of the study schedule
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percentage of FLP-CGM values that are less than
3.9 mmol/l with or without symptoms. All
patients receive FLP-CGM at baseline. Patients
who undergo ultrasonographic scans of the
carotid artery will be asked to receive FLP-CGM
at 104 weeks as an optional examination for an
exploratory analysis.
Measurement of Carotid IMT
Ultrasonographic scans of the carotid artery are
performed by expert sonographers who have
been specifically trained to perform the pre-
scribed study examination, as reported previ-
ously [13, 14]. To avoid inter-sonographer
variability, each participant is examined by the
same sonographer at all visits, using the same
equipment (high-resolution B-mode ultrasound
scanner equipped with a high-frequency
([7.5 MHz) linear transducer and with a limit
of detection of \0.1 mm). The extracranial
common carotid artery, the carotid bulb, and
the internal carotid artery in the neck are
scanned bilaterally in transverse projections
and in at least three different longitudinal pro-
jections (anterior, lateral, and posterior, which
approximately correspond to 60, 90, and 150
for the right carotid artery and 210, 270, and
300 for the left carotid artery, as marked on
Meijer’s arc). Additionally, the site of greatest
thickness (including plaque lesions) is identified
along the arterial walls. IMT represents the dis-
tance between two parallel echogenic lines
corresponding to the vascular lumen and the
adventitia. To avoid inter-reader variability, all
scans are stored electronically and emailed to
the central office (IMT Evaluation Committee,
Osaka, Japan) to be read in random order by a
single experienced reader blinded to the clinical
characteristics of the patients, using automated
digital edge-detection software (Intimascope;
MediaCross, Tokyo, Japan) [13, 14]. The soft-
ware system averages about 200 IMT values in
the segment 2 cm proximal to the dilation of
the carotid bulb (mean-IMT-CCA). In addition,
the greatest IMTs, including plaque lesions in
the common carotid arteries (max-IMT-CCA),
are also measured separately.
The echogenicity of the arterial wall is eval-
uated based on the grayscale median (GSM)
method with a grayscale range of 0–255 (0 as
the darkest tone and 255 as the brightest), as
described previously [15, 16]. Adobe Photoshop
software (version 7.0; Adobe Systems, San Jose,
CA, USA) is used for image standardization and
the calculation of grayscale values. The stan-
dardization of the B-mode image is performed
using a curve option, so that the GSM range for
the blood is 0–5 and that for the adventitia is
185–195 [17]. The mean-IMT-CCA area is then
delineated with a freehand tool, and the GSM of
the selected area is read from the entire delin-
eated area. Similarly, if there is an atheroscle-
rotic plaque lesion (i.e., a focal elevated lesion
with max-IMT-CCA[1.0 mm), the GSM of the
plaque lesion is also measured using the same
method. If multiple plaque lesions are found in
the same individual, the plaque with the
greatest thickness is subjected to GSM mea-
surement, and that GSM value is used as the
subject’s representative value. To avoid inter-
reader variability, all scans are stored electroni-
cally and read in random order by a single
reader who is unaware of the subjects’ clinical
characteristics and treatment groups.
Measurement of baPWV
In some participating centers, baPWV is mea-
sured using an automatic waveform analyzer
(Colin Medical Technology, Komaki, Japan), as
described previously [18]. Recording is per-
formed with the patients in the supine position
after a 5-min rest. Occlusion and monitoring
cuffs are placed snugly around the appropriate
areas on the upper and lower extremities. The
pressure waveforms are then recorded simulta-
neously from the brachial arteries by the oscil-
lometric method. All scans are automatically
conducted by well-trained investigators who are
blinded to the clinical information. Previous
studies have confirmed the validity and repro-
ducibility of baPWV measurements [19]. The
ankle–brachial index is also measured. A resting
ankle–brachial index of B 0.90 is considered to
indicate the presence of peripheral artery
disease.
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Coefficient of Variation of R–R Intervals
(CVR–R) on Electrocardiogram
CVR–R at rest is measured based on R–R inter-
vals from 100 electrocardiogram samples.
CVR–R, which reflects autonomic nerve func-
tion, is calculated as (standard deviation in R–R
)/(mean R–R interval) 9 100%.
Diabetes Therapy-Related Quality of Life
(DTR-QOL)
The DTR-QOL is a 29-item, self-administered
assessment with four primary scales, including
burden on social activities and daily activities
(13 items), anxiety and dissatisfaction with
treatment (8 items), hypoglycemia (4 items),
and satisfaction with treatment (4 items) [20]. It
has been demonstrated that the DTR-QOL can
be used to evaluate the effect of diabetes treat-
ment on patient QOL with high reliability and
validity [20].
Pittsburgh Sleep Quality Index (PSQI)
The PSQI is used to evaluate sleep quality in this
study [18, 21]. The PSQI is a self-administered
questionnaire that consists of 18 items relating
to 7 components: subjective sleep quality, sleep
duration, sleep onset, habitual sleep efficiency,
sleep disturbances, use of sleeping medications,
and daytime dysfunction. Each of these is
weighted equally on a 0–3 scale, and the sum
yields the global PSQI score, ranging from 0 to
21, with higher scores indicating worse sleep
quality. The PSQI has a high test–retest relia-
bility and a good validity [22].
Study Outcomes
The primary study outcome is the relationship
between fluctuations in glucose levels evaluated
by FLP-CGM and the incidence of composite
cardiovascular events, including cardiovascular
death, acute myocardial infarction, unsta-
ble angina pectoris, revascularization for the
treatment of coronary artery diseases, ischemic
stroke, and revascularization for the treatment
of arteriosclerosis obliterans.
The secondary outcomes are:
(1) The relationship between fluctuations in
glucose levels evaluated by FLP-CGM and
the incidence rates of the following com-
posite cardiovascular events (a, b, or c, or
each of a, b, and c):
(a) heart diseases (cardiovascular death,
acute myocardial infarction, unsta-
ble angina pectoris, revascularization
for the treatment of coronary artery
diseases, or hospitalization for heart
failure),
(b) cerebrovascular diseases (ischemic
stroke, hemorrhagic stroke, or sub-
arachnoid hemorrhage), and
(c) arterial diseases (arteriosclerosis
obliterans, revascularization for the
treatment of arteriosclerosis obliter-
ans, or ischemia-related lower limb
amputation (minor amputation and
major amputation));
(2) The relationship between fluctuations in
glucose levels evaluated by FLP-CGM and
the incidence of malignant tumors;
(3) The relationship between fluctuations in
glucose levels evaluated by FLP-CGM and
all-cause mortality in addition to (a) plus
(b) plus (c) as described above;
(4) The relationship between fluctuations in
glucose levels evaluated by FLP-CGM and
cardiovascular death, myocardial infarc-
tion, or stroke;
(5) The relationship between fluctuations in
glucose levels evaluated by FLP-CGM and
cardiovascular death, myocardial infarc-
tion, unstable angina, or stroke;
(6) The relationship between fluctuations in
glucose levels evaluated by FLP-CGM and
development or progression of diabetic
retinopathy or nephropathy. The devel-
opment of diabetic retinopathy is defined
as the transition from no diabetic
retinopathy at baseline to simple
retinopathy or pre-proliferative retinopa-
thy or proliferative retinopathy. The
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progression of diabetic retinopathy is
defined as worsening of the stage of
diabetic retinopathy. The development
of diabetic retinopathy is defined as the
transition from normoalbuminuria at
baseline to micro- or macroalbuminuria.
The progression of diabetic nephropathy
is defined as worsening of the stage of
diabetic nephropathy. Also, we will eval-
uate the decline in renal function (de-
fined as a decrease in eGFR of 30% from
baseline) and the eGFR slope (estimated
from all available serum creatinine mea-
surements over the study period) to
investigate the relationships between
fluctuations in glucose levels and those
parameters;
(7) The relationship between fluctuations in
glucose levels evaluated by FLP-CGM and
changes in mean-IMTCCA and max-IMT-
CCA, gray-scale median, or brachial-ankle
pulse wave velocity;
(8) The relationship between fluctuations in
glucose levels evaluated by FLP-CGM and
changes in DTR-QOL scores or PSQI
scores;
(9) The relationship between fluctuations in
glucose levels evaluated by FLP-CGM and
the development of dementia;
(10) The relationship between hypoglycemic
events and cardiovascular events; and
(11) The relationship between atherosclerotic
risk factors, Diabetes Therapy-Related
QOL scores or Pittsburgh Sleep Quality
Index scores, and cardiovascular events.
These secondary endpoints will be ana-
lyzed as prespecified exploratory end-
points.
The tertiary outcomes are the relation-
ships between fluctuations in glucose
levels evaluated by FLP-CGM and glucose
parameters, lipid parameters, renal func-
tion, diabetic microangiopathy, mean-
IMT-CCA and max-IMT CCA, gray-scale
median, brachial-ankle pulse wave veloc-
ity, DTR-QOL scores or PSQI scores, and
autonomic nerve function in cross-sec-
tional analysis.
Sample Size
The sample size was not calculated based on
scientific evidence because this is an explana-
tory study. The target number of enrolled
patients was tentatively set at about 1000 sub-
jects. We aimed to ensure that more than 35
composite cardiovascular events are included
because at least 20 events are required to obtain
meaningful results in multivariate Cox regres-
sion analysis [23]. According to our previous
study, the event rate was estimated to be about
4% during a 5.5-year follow-up period [24].
Assuming an exponential distribution, the
event rate would be about 3.64%, and 961 cases
would be required to include 35 events during
the 5-year follow-up. Therefore, considering
participant dropout, the target number of
enrolled patients was set at 1000 subjects.
Safety Evaluation
All adverse events (AEs) are to be recorded dur-
ing the study for the sake of patient safety. AEs
are defined as any untoward medical occurrence
in a clinical trial subject who has been admin-
istered a medicinal product. In particular, the
investigators are required to record AEs related
to the FLP device; as soon as these are con-
firmed, they must immediately be reported to
the principal investigator and the ethics com-
mittee within 15 days, who will judge whether
the diagnosis is appropriate and then make a
decision on whether the patient should with-
draw from the trial. Serious AEs are defined as
death or life-threatening events that necessitate
inpatient hospitalization, cause prolongation of
the existing hospitalization, or result in persis-
tent or significant disability/incapacity that
requires intervention to prevent permanent
impairment or damage.
Statistical Analysis
Analyses of study outcomes will be performed
mainly on the full analysis set. Univariate and
multivariate Cox proportional hazard models
will be used to determine the association of
glucose fluctuations with the primary outcome.
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Hazard ratios (HRs) and 95% confidence inter-
vals (CIs) will be reported. The cumulative
event-free rates of the primary outcome will be
estimated for different levels of glucose fluctu-
ation using the Kaplan–Meier method, and the
differences will be tested using the log-rank test.
Glucose fluctuations will be expressed as
MAGE, CV, SD, ADRR, and M values. To evalu-
ate the model fit and the ability of these
parameters to predict the incidence of com-
posite cardiovascular events, a time-dependent
receiver operating characteristic (ROC) curve
analysis will be performed and Akaike’s infor-
mation criterion (AIC) values will be calculated.
The secondary outcomes will be analyzed in
the same manner as the primary outcome. The
correlations between glucose fluctuation param-
eters and various parameters, including mean
carotid IMT, maximum carotid IMT, GSM, and
baPWV, will be evaluated using Pearson’s and
Spearman’s correlation coefficients.
In the exploratory study, the time trajecto-
ries of glucose fluctuation will be evaluated
using the glucose fluctuation parameters at
baseline and at 104 weeks. The correlation
between change in glucose fluctuation param-
eters and changes in carotid echo parameters
(mean carotid IMT, maximum carotid IMT,
GSM, and baPWV) from baseline to 104 weeks
will be also evaluated.
All statistical tests will be two-sided with a
significance level of 5%. All analyses will be
performed using SAS software (version 9.4 or
above; SAS Institute, Cary, NC, USA).
STRENGTHS AND LIMITATIONS
OF THE STUDY PROTOCOL
The strength of this protocol is its large-sample,
prospective, multicenter study design involving
repeated clinical measurements such as risk
factors for atherosclerosis and a 5-year follow-
up period. On the other hand, our study pro-
tocol has certain limitations. The primary limi-
tation of our study protocol is its explanatory
nature. There are no reports to suggest that
glucose fluctuations are related to the incidence
of CVD or progression of atherosclerosis in
patients with T2DM with no apparent history of
CVD. This made it difficult to calculate the
sample size besed on scientific evidence. In
addition, it is still unclear which parameters of
glucose fluctuations evaluated by FLP-CGM are
useful in terms of predicting the incidence of
CVD in patients with T2DM who have no
apparent history of CVD. Thus, we will evaluate
the ability of glucose fluctuation markers to
predict the incidence of composite cardiovas-
cular events. Second, glucose fluctuations will
be evaluated by limited FLP-CGM measure-
ments. One of the reasons for this is practical
constraints, including study costs. However, we
are focusing on investigating the ability of glu-
cose fluctuation parameters measured by FLP-
CGM at baseline to predict the incidence of
composite cardiovascular events. In order to
attain the best measurements of glucose fluc-
tuations by FLP-CGM at baseline, we recruited
patients whose antidiabetic medications were
unchanged for 6 months before written infor-
mation consent was obtained. Those subjects
are expected to have stable glucose control.
Third, we only recruited Japanese patients with
T2DM. These constraints may limit the gener-
alizability of our results.
CONCLUSIONS
We had completed the registration of 1000
participants in March 2019, and the results will
be available in 2024. We expect that glucose
fluctuations at baseline will be a risk factor for
CVD and progression of atherosclerosis, and
may even be an independent risk factor for
these conditions after adjusting for other
atherosclerotic risk factors. If our results support
the hypothesis that early intervention targeting
glucose fluctuations can decrease the incidence
of CVD in patients with T2DM, these findings
will contribute to establishing a better social
healthcare system and to extending patients’
healthy lifespans.
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